Novel promising biomarkers in endometrial cancer - review

Dominika Krawczyk, Agnieszka Kwiatkowska


Introduction: Endometrial carcinoma is the most common gynaecological neoplasm in developed countries. The disease is mostly asymptomatic at an early stage, however there is no direct marker which could result in detection of cancer earlier. Nowadays the diagnosis is based on the histopathological results of endometrial biopsy.
Purpose: The aim of the review was to present the noticable studies that have showed the molecular markers and their usefulness in treatment options of endometrial cancer. We will review the current status of biomarkers which may be helpful in early diagnostic and further therapy of endometrial cancer.
State of knowledge: There have been many promising biomarkers which were described in newest studies. TFL is a tumor suppressor gene that contributes to cell-cycle arrest and RNA regulations. CD44 and JAK2 may be liked with neovascularity in distance tissue. Elevated levels of TGM2 and ASRGL1 are associated with an aggressive cancer phenotype and drug resistance in endometrial cancer. Additionally, the level of EpCAM were significantly increased in endometrial cancer sample comparing to control samples. AURKA results in resistance to anticancer agents including paclitaxel and docetaxel used in cancer treatment.
Summary: Endometrial cancer is a common problem among gynecological patients. There is no explicit marker which could directly contribute to biologic aggressiveness and response to treatments of that cancer. Presented molecules could potentially be a candidates biomarkers for diagnosis and further treatment of endometrial cancer. However, it is crucial to intensify affords to better understand the impact of these markers. Which could lead to significant improvement of patient’s survival and better quality of life.


Biomarkers; endometrial cancer; novel plasma markers

Full Text:



Reclassifying endometrial carcinomas with a combined morphological and molecular approach Joseph Carlsona,b and W. Glenn McCluggagec

Bulletin du Cancer Volume 104, Issue 12, December 2017, Pages 1022-1031 Bulletin du Cancer Synthèse Cancer de l’endomètre de stade précoce : implication clinique des modèles prédictifsEndometrial cancer: Predictive models and clinical impact, SofianeBendifallah1MarcosBallester12EmileDaraï12 (12.07.2019) (12.07.2019)

Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of endometrial cancer. Jacek Jan Sznurkowski, Paweł Knapp, Lubomir Bodnar, Mariusz Bidziński, Robert Jach et all, Curr Gynecol Oncol 2017, 15 (1), p. 34–44

B. Trabert, N.Wentzensen, A.S. Felix, H.P. Yang,M.E. Sherman, L.A. Brinton,Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database, Cancer Epidemiol. Biomark. Prev. 24 (2015) 261–267.

L.A. Brinton, B. Trabert, G.L. Anderson, et al., Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women, Cancer Epidemiol. Biomark. Prev. 25 (2016) 1081–1089.

Colombo N, Creutzberg C, Amant F et al.; ESMO-ESGOESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27: 16–41.

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10–17.

Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer; 2014.

Reclassifying endometrial carcinomas with a combined morphological and molecular approach Joseph Carlsona,b and W. Glenn McCluggagec

Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013; 37:874–881.

Thomas S, Hussein Y, Bandyopadhyay S, et al. Interobserver variability in the diagnosis of uterine high-grade endometrioid carcinoma. Arch Pathol Lab Med 2016; 140:836–843.

Cancer Genome Atlas Research Network. Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73.

R. Murali, R.A. Soslow, B. Weigelt, Classification of endometrial carcinoma: more than two types, Lancet Oncol. 15 (2014) e268–e278.

C. Kandoth, N. Schultz, A.D. Cherniack, et al., Integrated genomic characterization of endometrial carcinoma, Nature 497 (2013) 67–73.

Lucas E, Chen H, Molberg K, et al. Mismatch repair protein expression in endometrioid intraepithelial neoplasia/atypical hyperplasia: should we screen for lynch syndrome in precancerous lesions? Int J Gynecol Pathol 2018; 1–10;

Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative. Mod Pathol 2015; 28:636–644.

Lucas E, Chen H, Molberg K, et al. Mismatch repair protein expression in endometrioid intraepithelial neoplasia/atypical hyperplasia: should we screen for lynch syndrome in precancerous lesions? Int J Gynecol Pathol, 2018; 1–10;

Creasman WT. Prognostic significance of hormone receptors in endome- trial cancer. Cancer 1993;71:1467–70.

Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggres- sive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199:543.

Kauppila AJ, Isotalo HE, Kivinen ST, Vihko RK. Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 1986;46:5380–4.

Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, et al. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 2013;19:1094–105.

Minagawa K, Katayama Y, Nishikawa S, Yamamoto K, Sada A, Okamura A, et al. Inhibition of G1 to S phase progression by a novel zinc finger protein p58TFL at P-bodies. Mol Cancer Res 2009; 7:880–9.

Senn Wakahashi, Fumi Kawakami, Kanako Wakahashi, Kentaro Minagawa, Keitaro Matsuo, Yoshio Katayama, Hideto Yamada, Toshimitsu Matsui and Tamotsu Sudo Transformed Follicular Lymphoma (TFL) Predicts Outcome in Advanced Endometrial Cancer Cancer Epidemiol Biomarkers Prev August 1 2018 (27) (8) 963-969; doi: 10.1158/1055-9965.EPI-17-0762

Minagawa K, Katayama Y, Matsui T. TFL, a hidden post-transcriptional modulator behind inflammation. Inflammation and cell signaling 2014;1: e244.

Underhill, C. (1992). CD44: the hyaluronan receptor. J. Cell. Sci. 103(Pt 2), 293–298.

Iczkowski, K. A. (2010). Cell adhesion molecule CD44: its functional roles in prostate cancer. Am. J. Transl. Res. 3, 1–7.

Senbanjo, L. T. & Chellaiah, M. A. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol 5, 18, (2017).

Thorne, R. F., Legg, J. W., and Isacke, C. M. (2004). The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J. Cell Sci. 117(Pt 3), 373–380. doi: 10.1242/jcs.00954

CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis Anna Torres1,2,3,5*, Małgorzata Pac-Sosińska1, Krzysztof Wiktor4, Tomasz Paszkowski2, Ryszard Maciejewski1 and Kamil Torres1

Wojciechowski M, Krawczyk T, Śmigielski J, Malinowski A. CD44 expression in curettage and postoperative specimens of endometrial cancer. Arch Gynecol Obstet. 2015;291:383–90.

Elbasateeny SS, Salem AA, Abdelsalam WA, Salem RA. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathol Res Pract. 2016;212:10–6.

Liesveld, J. L., Frediani, K. E., Harbol, A. W., DiPersio, J. F., and Abboud, C. N. (1994). Characterization of the adherence of normal and leukemic CD34+ cells to endothelial monolayers. Leukemia 8, 2111–2117.

Trochon, V., Mabilat, C., Bertrand, P., Legrand, Y., Smadja-Joffe, F., Soria, C., et al. (1996). Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int. J. Cancer 66, 664–668. doi: 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4

Savani, R. C., Cao, G., Pooler, P. M., Zaman, A., Zhou, Z., and DeLisser, H. M. (2001). Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J. Biol. Chem. 276, 36770–36778. doi: 10.1074/jbc.M102273200

Cao, G., Savani, R. C., Fehrenbach, M., Lyons, C., Zhang, L., Coukos, G., et al. (2006). Involvement of endothelial CD44 during in vivo angiogenesis. Am. J. Pathol. 169, 325–336. doi: 10.2353/ajpath.2006.060206

Gupta, A., Cao, W., and Chellaiah, M. A. (2012). Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis. Mol. Cancer 11:66. doi: 10.1186/1476-4598-11-66

Greenberg CD, Birckbichler PJ, Rice RH. Transglutaminases: mul- tifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991; 5: 3071-7.

Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003; 4: 140- 56.

Belkin AM Extracellular TG2: emerging functions and regulation. FEBS J. 2011;278:4704–16. Huang L, Xu AM, Liu W. Transglutaminase 2 in cancer. Am J Cancer Res. 2015; 5: 2756-76.

Huang L, Xu AM, Liu W. Transglutaminase 2 in cancer. Am J Cancer Res. 2015; 5: 2756-7

Eckert RL, Fisher ML, Grun D, Adhikary G, Xu W, Kerr C. Trans- glutaminase is a tumor cell and cancer stem cell survival factor. Mol Carcinog. 2015; 54: 947-58.

Colligham RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids. 2009; 36: 659-70.

Momburg F, Moldenhauer G, Hammerling GJ, Moller P: Immunohis- tochemical study of the expression of a Mr 34,000 human epithelium- specific surface glycoprotein in normal and malignant tissues. Can- cer Res 1987, 47:2883–2891

Wang MH, Sun R, Zhou XM, Zhang MY, Lu JB, Yang Y, Zeng LS, Yang XZ, Shi L, Xiao RW, Wang HY, Mai SJ (2018). Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway. Cell Death Dis 9(1): 2. doi: 10.1038/s41419-017-0013-8

Sasnauskiene A, Jonušienė V, Krikštaponienė A, Butkyte S, Dabkevičienė D, Kanopiene D, et al. NOTCH1, NOTCH3, NOTCH4, and JAG2 protein levels in human endometrial cancer. Medicina. 2014;50:14–8.

Zou J, Li P, Lu F, Liu N, Dai J, Ye J, et al. Notch1 is required for hypoxia- induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:1–13.

PietrasA,vonStedingkK,LindgrenD,PåhlmanS,AxelsonH.JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation. Mol Cancer Res. 2011;9:626–36.

Vaish V, Kim J, Shim M. Jagged-2 (JAG2) enhances tumorigenic- ity and chemoresistance of colorectal cancer cells. Oncotarget. 2017;8:53262–75.

Sagert J, West J, Wong C, Desnoyers L, Vasiljeva O, Richardson J, et al. Abstract 2665: transforming Notch ligands into tumor-antigen targets: a Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2. Cancer Res. 2014;74:2665.

JonusieneV,SasnauskieneA,LachejN,KanopieneD,DabkevicieneD, Sasnauskiene S, et al. Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol. 2013;30:438.

Townsend MH, Ence ZE, Felsted AM, Parker AC, Piccolo SR, Robison RA, et al. Potential new biomarkers for endometrial cancer. Cancer Cell Int. 2019; 19:19. Epub 2019/01/27.

Marumoto t, Zhang D and Saya H: aurora-a - a guardian of poles. nat rev cancer 5: 42-50, 2005.

Townsend MH, Felsted AM, Ence ZE, Piccolo SR, Robison RA, O’Neill KL. Elevated expression of hypoxanthine guanine phosphoribosyltransferase within malignant tissue. Cancer Clin Oncol. 2017;6:19.

Do TV, Xiao F, Bickel LE, et al: aurora kinase a mediates epithelial ovarian cancer cell migration and adhesion. oncogene 33: 539-549, 2014.

Anand S, Penrhyn-lowe S and Venkitaraman ar: aurora-a ampli cation overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. cancer cell 3: 51-62, 2003.

Lin y, richards fM, Krippendorff Bf, et al: Paclitaxel and cyc3, an aurora kinase a inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Br J Cancer 107: 1692‐1701, 2012.

Long M, yin g, liu l, et al: adenovirus-mediated aurora a shrna driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells. Cancer Gene Ther 19: 271‐281, 2012.

Tanaka e, Hashimoto y, ito t, et al: the suppression of aurora-a/StK15/BtaK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 13: 1331‐1340, 2007.

Umene K, Banno K, Kisu i, et al: aurora kinase inhibitors: potential molecular-targeted drugs for gynecologic malignant tumors. Biomed rep 1: 335-340, 2013.

Kurai M, Shiozawa t, Shih Hc, et al: expression of aurora kinases a and B in normal, hyperplastic, and malignant human endometrium: aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 36: 1281-1288, 2005.

Moreno-Bueno g, Sánchez-estévez c, cassia r, et al: Differential gene expression pro le in endometrioid and nonendometrioid endometrial carcinoma: StK15 is frequently overexpressed and ampli ed in nonendometrioid carcinomas. Cancer Res 63: 5697‐5702, 2003.

Umene K, Yanokura M, Banno K, Irie H, Adachi M, Iida M, et al. Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. Int J Oncol. (2015) 46:1498– 506. doi: 10.3892/ijo.2015.2842

J.R. Cantor, E.M. Stone, L. Chantranupong, G. Georgiou, The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity, Bio- chemistry 48 (2009) 11026–11031.

H.B. Salvesen, S.L. Carter, M. Mannelqvist, A. Dutt, G. Getz, I.M. Stefansson, et al., In- tegrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 4834–4839.

E. Wik, J. Trovik, K. Kusonmano, E. Birkeland, M.B. Raeder, I. Pashtan, et al., Endome- trial carcinoma recurrence score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alter- ations, Gynecol. Oncol. 134 (2014) 599–606.

P.H. Edqvist, J. Huvila, B. Forsstrom, L. Talve, O. Carpen, H.B. Salvesen, et al., Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma, Gynecol. Oncol. 137 (2015) 529–537

Fonnes T, Berg HF, Bredholt T, Edqvist P-HD, Sortland K, Berg A, et al. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecol Oncol. 2018; 148: 197–203. PMID: 29096882



  • There are currently no refbacks.

Copyright (c) 2019 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski